akampion News

Please click here to subscribe to regular news updates from the akampioneer.com
Thursday, September 18, 2014

Company News: Patent Position of Merus’ MeMo® Mouse Strengthened by Ruling of European Patent Office

- Freedom to operate confirmed

- Successful opposition against Regeneron’s patent EP 1 360 287 B1 for transgenic mice producing therapeutic human antibodies

Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, announced today that it has successfully retained full freedom to operate for its proprietary transgenic MeMo® mouse. In opposition proceedings at the European Patent Office, the opposition division ruled on September 17 that European patent EP 1 360 287 B1, owned by Regeneron Pharmaceuticals Inc., was revoked in its entirety.

In 2012, Regeneron was granted a European patent entitled “Methods of Modifying Eukaryotic Cells”. The patent is part of Regeneron’s IP portfolio around its VelocImmune® mouse for therapeutic human antibodies. Merus filed an opposition against this patent in June 2013, thereby requesting revocation of the patent.

Tuesday, September 16, 2014

Company News: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT

-      Field-based trial with 196 patients shows significant reductions in seasonal allergy symptoms

-      Efficacy of AllerT in both dose groups maintained during the second birch pollen season

Anergis, a company developing proprietary ultra-fast allergy vaccines, today reported positive long-term efficacy results with its lead compound AllerT, a novel birch pollen allergy vaccine.

A total of 196 patients were enrolled in the Phase IIb follow-up, double-blind, placebo-controlled, field-based clinical trial. The trial objective was to evaluate the long-term efficacy of AllerT in patients who had participated last year in the field-based Phase IIb trial with AllerT. Patients evaluated this year either received a placebo, AllerT 50 µg or AllerT 100 µg 18 months before the second birch pollen season. No further investigational treatment was given after the initial randomization.